Sources and small print

1. Results are based on the SURMOUNT-1 Mounjaro trial. Results vary – weight loss can be more or less than the 21% average.

Jastreboff, A.M. et al. (2022) "Tirzepatide Once Weekly for the Treatment of Obesity" New England Journal of Medicine, 387(3)

https://doi.org/10.1056/NEJMoa2206038

2. Results are based on the STEP 1 Wegovy trial. Results vary – weight loss can be more or less than the 15% average.

Wilding, J.P.H. et al. (2021) "Once-weekly semaglutide in adults with overweight or obesity" New England Journal of Medicine, 384(11)

https://doi.org/10.1056/NEJMoa2032183.

3. Valabhji, J. et al. (2024) "Early findings from the NHS Type 2 Diabetes Path to Remission Programme: a prospective evaluation of real-world implementation" The Lancet, 12(9) https://doi.org/10.1016/S2213-8587(24)00194-3

* Coming soon.

** 10% to 15% weight loss over a period of 12 months. It is important to commit to the full 12 months of ongoing support to ensure that your hard work in the total meal replacement phase and the food reintroduction stages thereafter have resulted in long term sustainable weight loss. Studies show that people keep more weight off when they engage in a full year-long programme.

*** Price may increase or decrease subject to market conditions.

**** Maximum of one consultation per week with no carry-over of unused appointments.